Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL), drawn from the whole corpus: 5 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Whether chemotherapy-free kinase inhibitor plus blinatumomab regimens can replace intensive chemotherapy in children.
Kinase domain resistance mutations and the lack of paediatric approval for ponatinib.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Resistance atlas · Lines of therapy.
Long-term effects of kinase inhibitors on growth, bone and heart.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 11 changes by month →When this page itself was last checked or edited.
MRD-negative CR 34.
A milestone in how this cancer is treated.
18-month OS 95%, DFS 88%.
A milestone in how this cancer is treated.
Imatinib with BFM chemotherapy gave four-year disease-free survival of 72.